Home Stocks Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd

The live share price of Torrent Pharmaceuticals Ltd (TORNTPHARM) as on 29 Sep 10:26am is ₹1,929.1 from NSE/BSE.

TORNTPHARM NSE

₹1,929.1 ▲3.51% (65.5)

As on Sep 29, 2023 03:56 PM IST

How do you feel today about Torrent Pharmaceuticals Ltd?

Bearish or

Bullish

Bearish or

Bullish

Key Metrics

PE Ratio

49.7

PB Ratio

10.18

Dividend Yield

1.18%

Sector PB

4.66

Sector PE

39.72

Sector Div Yld

0.78%

Dividend Yield

Dividend per share for the most recent financial year divided by the close price

About

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Midcap, ₹63,072 Cr

Torrent Pharmaceuticals Limited is engaged in the manufacture and sale of branded, as well as unbranded generic pharmaceutical products.

The following charts display the financial performance of the Torrent Pharmaceuticals Ltd (TORNTPHARM) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.

Furthermore, under the Peers section, you can find stocks that are similar to Torrent Pharmaceuticals Ltd (TORNTPHARM), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.

✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.

A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.

All smallcases are created and managed by SEBI-registered investment experts.

To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Midcap, ₹63,072 Cr

Financials

Income Statement

(INR)		Y/Y Change
Revenue	9,665 Cr	+11.04%
Operating Expense	873 Cr	-29.79%
Net Income	1,245 Cr	+60.22%
Net Profit Margin	12.88%	+44.23%
Earning Per Share	36	+60.21%
EBITDA	2,887 Cr	+34.72%

Balance sheet

(INR)		Y/Y Change
Cash & short-term Inv	727 Cr	+23.86%
Total Assets	14,609 Cr	+13.2%
Total Liabilities	8,411 Cr	+20.98%
Total Equity	6,198 Cr	+4.12%
Shares Outstanding	33.84 Cr	-0.01%
Price to Book	8.39	+5.91%
Return on Assets	9.05%	+57.12%
Return on Capital	35.18 Cr	+41.4%

Cash Flows

(INR)		Y/Y Change
Net Income	1,245 Cr	+60.22%
Cash from Operations	2,368 Cr	+31.34%
Cash from Investing	-2,335 Cr	+1090.9%
Cash from Financing	77 Cr	-104.34%
Net Change in Cash	110 Cr	-163.23%
Free Cash Flow	1,794 Cr	+12.11%

Shareholding Pattern

Total Promoter Holding

71.25%

Unpledged

Foreign Institutions

12.84%

Foreign Institutions

Retail & Others

7.6%

Retail & Others

Other Parties

Other Domestic Institutions

2.73%

Insurance Firms

Others

Mutual Funds

5.59%

Mutual Funds

Peers

SUNPHARMA

Sun Pharmaceutical Industries Ltd

PE Ratio

32.21

1Y Return

▲24.49%

CIPLA

Cipla Ltd

PE Ratio

30.21

1Y Return

▲6.3%

DRREDDY

Dr Reddy's Laboratories Ltd

PE Ratio

19.13

1Y Return

▲28.12%

MANKIND

Mankind Pharma Ltd

PE Ratio

47.88

1Y Return

▲24.06%

Latest News

Torrent Pharma - Visualising A Deal With Cipla; Key Positives, Negatives: Yes Securities Analysis

3 weeks ago on Bloomberg Quint

Change since news ▼-3.01%

Upfront, deal would require large capital outlay to buy out promoter stake followed by an open offer.

Cipla acquisition: Report warns of EPS dilution despite funding as Torrent Pharma and Dr Reddy’s eye pharma major

3 weeks ago on Business Today

Change since news ▼-0.37%

Kotak Institutional Equities found minimal portfolio overlap between Torrent Pharma and Cipla, thus limiting synergies

Torrent Pharma, Cipla, Sun Pharma Retain ‘Buy’ From HSBC On U.S. Demand

1 month ago on Bloomberg Quint

Change since news ▲1.48%

HSBC Global Research expects the robust growth in U.S. sales to persist.

Stocks in news: Tata Motors, Coforge, RIL, Torrent Pharma, TVS Motor and more

1 month ago on Business Today

Change since news ▲0.48%

Stocks to watch out for today: RIL, Torrent Pharma, TVS Motor, JB Pharma, Tata Motors, Coforge, Tata Communications and more

Torrent Pharma says US FDA issues ‘EIR’ for company’s manufacturing facility

1 month ago on Economic Times

Change since news ▲0.48%

Torrent Pharmaceuticals on Thursday said that the US Food and Drug Administration (US FDA) has issued an Establishment Inspection Report (“EIR”) for the company’s manufacturing facility at Dahej, Gujarat. EIR means closure of inspection.

Torrent Pharmaceuticals Gets EIR From US FDA For Dahej Facility

1 month ago on Free Press Journal

Change since news ▲0.48%

The updated classification of the site is VAI (voluntary action indicated) which indicates that Torrent will start to get approval of filed ANDAs.

How A Potential Acquisition Of Cipla Would Impact Torrent Pharma

1 month ago on Bloomberg Quint

Change since news ▲0.48%

While an official confirmation is awaited, at least two analysts said the deal may be too big for Torrent Pharma.

Torrent Pharmaceutical gains on USFDA relief for Dahej plant

1 month ago on Moneycontrol

Change since news ▲0.48%

The FDA’s ‘voluntary action indicated classification’ means that Torrent Pharma will be now able to get approval for all pending Abbreviated New Drug Applications from the site

Deal street abuzz on Torrent Pharma’s possible interest in Cipla promoter stake

1 month ago on The Hindu Businessline

Change since news ▲0.45%

Torrent Pharma shows interest in Cipla; PE players keen on buying promoter stake. If successful, it would change dynamics of domestic pharma industry. Torrent has pulled off several domestic acquisitions, incl. Elder Pharma & Unichem. Last year, bought Curatio Healthcare for Rs ₹2000 crore. Reports …

Torrent Pharma joins race to acquire stake of Cipla promoters: Report

1 month ago on Business Today

Change since news ▲2.4%

A successful deal will take Torrent Pharma to the second-largest company by revenues in India. In domestic formulation business, it will overtake market leader Sun Pharma.

FAQs on Torrent Pharmaceuticals Ltd

How to buy Torrent Pharmaceuticals Ltd stocks?

You can easily buy the stocks/shares of Torrent Pharmaceuticals Ltd (TORNTPHARM) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.

What is the Share Price of Torrent Pharmaceuticals Ltd?

The stock price of Torrent Pharmaceuticals Ltd as on 29 Sep 2023 is ₹1,929.1

What is the 52-week High and Low of Torrent Pharmaceuticals Ltd?

The 52-week high and low of Torrent Pharmaceuticals Ltd (TORNTPHARM) is ₹2,094.55 and ₹1,445.55.

What is the PE and PB ratio of Torrent Pharmaceuticals Ltd?

The P/E (price-to-earnings) and P/B (price-to-book) ratios of Torrent Pharmaceuticals Ltd are 49.7 and 10.18 respectively.

What are the peers or stocks similar to Torrent Pharmaceuticals Ltd?

The peers or stocks similar to Torrent Pharmaceuticals Ltd are Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Mankind Pharma Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.

Which sector does Torrent Pharmaceuticals Ltd belong to?

Torrent Pharmaceuticals Ltd (TORNTPHARM) belongs to the Pharmaceuticals sector.

What is the Market Cap of Torrent Pharmaceuticals Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Torrent Pharmaceuticals Ltd (TORNTPHARM) is ₹63,072 Cr as of 29 Sep 2023

Can't decide whether or not to buy Torrent Pharmaceuticals Ltd stocks? ⭐️

Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.

Dislaimer: This platform is intended for informational purposes only and is not intended to provide investment advice. The stock prices displayed are delayed and may not reflect the most current market conditions. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. You can also consider consulting a financial advisor before making any investment decisions. Smallcase Technologies Private Limited shall not be responsible for any losses that may occur as a result of using this platform.